

WNT Signaling-Cell Cycle: Regulator of Cancer

Satarupa Gogoi

Department of Biotechnology, Lovely Professional University, Jalandhar, Punjab, India

Review Article

Received: 25/11/2016

Revised: 02/12/2016

Accepted: 07/12/2016

*For Correspondence

Satarupa Gogoi, M.tech,
Department of Biotechnology,
Lovely Professional university,
Jalandhar, Punjab, India, Tel:
91+ 9888596953.

E-mail:

gogoisatarupa@gmail.com

Keywords: Cancer, Wnt-pathway,
Cell cycle, glycol-lipoproteins,
Cell signalling

ABSTRACT

Cell differentiation, tissue morphogenesis, and tissue homeostasis requires growth factor. Irregularity of intracellular signal transduction can cause formative disturbances amid embryogenesis or specific ailments in the grown-up. One group of developed components vital for these viewpoints is given by the Wnt proteins. Specifically, Wnts have significant roles in stem cell biology, cardiac advancement and differentiation, angiogenesis, cardiovascular hypertrophy, cardiac failure, and maturing. Here, in this article the main aim is to present a cutting edge outlining of the present learning of the role of intracellular Wnt-mediated signaling system in cancer augmentation and prevention. The study shows that the subdivision into canonical and non-canonical Wnt signaling pathways solely based on the identity of Wnt ligands or Frizzled receptors is not fitting any longer. Moreover, it gives a platform to study the occurrence and prevention of cancer at the cellular and genomic level within the cell cycle.

INTRODUCTION

Cancer is essentially an outcome of uncontrolled cell division. Each cell in the body experiences an existing cycle. Cells develop and gap to supplant cells that are lost on account of normal damage or harm. Diverse cells develop and die at various rates. A few cells, for example, epithelial cells, divide rapidly whereas other cells, like nerve cells, develop gradually. Both normal cells and tumor cells experience a grouping of steps, or stages, when they shape new cells. This is known as the cell cycle [1]. The cell cycle includes an arrangement of sub-atomic and biochemical signaling pathways and they are G1, or crevice, stage, in which the cell develops and gets ready to orchestrate DNA; the S, or union, stage, in which the cell integrates DNA; the G2, or second stage, in which the cell gets ready to separate; and the M, or mitosis stage, in which cell division happens [2].

Normal tissue is comprised of cells that are in the resting stage (G^0) and cells that are isolating or passing on. There is a parity of partitioning cells and dying cells in normal tissue. Tumor can happen when there is no more a harmony amongst separating and passing on cells. The tissue can begin to develop to shape a tumor made up of unusually developing and partitioning cells. Hence diseased cells cannot enter G^0 and consequently start to separate wildly resulting in abnormalities.

Its improvement and movement are generally connected to a progression of changes in the action of cell cycle controllers. For example, inhibitors of the cell cycle prevent cells from partitioning when conditions are not favorable, so action of these inhibitors can advance disease. Also, these positive controllers of cell division can prompt growth in the event as they are excessively dynamic. These adjustments in movement are because of changes in the characteristics that encode cell cycle controller proteins. Growth becomes additionally a metabolic illness where oncogenic signaling pathways control vitality creation and macromolecular amalgamation to aid the multiplication of tumors.

There is an intricate exchange between cell cycle and Wnt signaling. Signaling by the Wnt group of emitted glycol-lipoproteins is one of the crucial systems that immediate cell proliferation, cell division and cell fate determination amid embryonic improvement, tissue homeostasis and malignancy [3]. With respect to proliferation, there is expanding proof for an unpredictable communication between accepted Wnt signaling and the cell cycle. Mitogenic Wnt signaling manages cell multiplication by advancing G1 stage. During mitosis, parts of the Wnt signaling process work directly in shaft development. Additionally, Wnt signaling is distinctly enacted in mitosis, proposing that 'mitotic Wnt signaling' assumes a critical part to organize a cell division program. Here the review states the exchange between Wnt signaling and the cell cycle [4].

WNT signaling was found in tumor models and has been perceived as a controller of malignancy improvement and movement. WNT signaling assumes a huge part in the reinventing the malignancy cell digestion system and signaling pathways are significant part of tumor bioenergetics. WNT characteristics encode emitted glycoproteins that sign through a variety of receptors and co-receptors to inspire control over cell proliferation, undifferentiated self-recharging cell body, and cell separation in an assortment of tissues [5]. An intracellular transcriptional coactivator called β -catenin acts as a shared factor in the actuation of signal translation [6]. Wnt pathway is authoritative Wnt signaling, which plays its role by controlling the measure of the transcriptional coactivator β -catenin that controls key formative signal expression programs [7]. The WNT/ β -catenin pathway is ordinarily alluded to as the authoritative WNT pathway, while the non-canonical pathway is an umbrella term for β -catenin-free WNT signaling which has risen as a basic controller of undifferentiated cells [5,8]. It was accounted for that Wnt pathway is indispensably required in both immature microorganism and tumor cell upkeep and development in the intestinal, epidermal and hematopoietic frameworks which may serve as a worldview for comprehension of the double way of self-reestablishment signals [8].

WNT SIGNALING MECHANISM

Wnt signaling starts when a Wnt protein ties to the N-terminal additional cell cysteine-rich space of a Frizzled (Fz) family receptor [9]. These receptors traverse the plasma membrane several times and constitute a well-defined group of G-protein coupled receptors (GPCRs) [10]. Moreover, to encourage Wnt signaling, co-receptors are required during the association between the Wnt protein and Fz receptor. Illustrations incorporate lipoprotein receptor-related protein (LRP)-5/6, receptor tyrosine kinase (RTK), and ROR2 [11,12]. Endless supply of the receptors sends a signal to the phosphoprotein Disheveled (Dsh), which is situated in the cytoplasm. This signal is transmitted by means of an immediate connection between Fz and Dsh. Dsh proteins are available in all life forms and they all share the accompanying much rationed protein areas: an amino-terminal DIX space, a focal PDZ space, and a carboxy-terminal DEP area. These diverse domains are imperative considering the fact that after Dsh, the Wnt sign can segment out into various pathways and every pathway collaborates with an alternate blend of the three domains.

The three best described Wnt signaling pathways are the authoritative Wnt pathway, the non-canonical planar cell extremity pathway, and the non-canonical Wnt/calcium pathway. As their names propose, these pathways have a place with one of two classes: standard or non-canonical. The contrast between the classes is that an accepted pathway includes the protein β -catenin while a non-canonical pathway works freely of it.

It has been accounted for in numerous inquiries that without Wnt, cytoplasmic β -catenin protein is always dissipated by the activity of the Axin complex, which is made out of the platform protein Axin, the tumor silencer adenomatous polyposis coli signal item (APC), casein kinase 1 (CK1), and glycogen synthase kinase 3 (GSK3). CK1 and GSK3 consecutively phosphorylate the amino terminal area of β -catenin, bringing about β -catenin acknowledgment by β -Trcp, an E3 ubiquitin ligase subunit, and consequent β -catenin ubiquitination and proteasomal dissipation [13]. This consistent end of β -catenin keeps β -catenin from reaching the nucleus, and Wnt target genes are subsequently curbed by the DNA-bound T cell component/lymphoid enhancer variable (TCF/LEF) group of proteins (Figure 1a). The Wnt/ β -catenin pathway is actuated when a Wnt ligand ties to a transmembrane Frizzled (Fz) receptor and its co-receptor, low-thickness lipoprotein receptor related protein 6 (LRP6) or its relative LRP5. The development of a reasonable Wnt-Fz-LRP6 complex together with the enlistment of the scaffolding protein Disheveled (Dvl) results in LRP6 phosphorylation and initiation and the enrollment of the Axin complex to the receptors. These phenomena lead to hindrance of Axin-intervened β -catenin phosphorylation and consequently to the adjustment of β -catenin, which gathers and moves to the nucleus to form complex with TCF/LEF and initiates Wnt target signal expression [14].

Cell-cycle movement is controlled by cyclins and their CDKs. In G₁, cyclin D starts Rb complex phosphorylation, which derepresses E2F to actuate cyclin E interpretation. The study leads to confusion and uncertainty in the activities of these elements and in addition p21 and p27 restrict these impacts and can bring about cell-cycle way out to G₀ phase. After DNA replication in S stage, distinctive signal controls guarantee the integrity of the DNA, while a cyclin B/CDK1 complex arranges movement into mitosis. Chromosome variations from the midpoint and DNA damage are accounted for to this complex through various pathways to defer or stop cell division and G₁-S stage movement by Wnt signaling. GSK3 hindrance by Wnt signaling occurs in the center for G₁ control. GSK3 hinders or initiates the demonstrated proteins, all of which can add to G₁-to S-stage movement. GSK3 target proteins which cannot be controlled by Wnt ligands can be seen in cell complexes. APC and Dvl manage the connection of the mitotic spindle to the kinetochores, and together with Fzd and LRP6 regulate shaft introduction. GSK3, β -catenin, and Axin2 are required at the centrosome to guarantee an appropriate conveyance of the chromosomes amid division. Wnt/GSK3 signaling microtubule gets together by tau adjustment. Hindrance of Wnt signaling or transformations in the showed segments trade off the mitotic spindle and can bring about chromosome instability [15].

Wnt/ β -catenin signaling directs cell multiplication by tweaking the cell cycle and is adversely controlled by conductin/axin2/axil. The conductin levels crest at G2/M followed by a rapid decline during return to G1. In accordance with this, Wnt/ β -catenin target genes are low at G2/M and high at G1/S, and β -catenin phosphorylation sways amid the cell cycle in a conductin-subordinate way. Conductin is degraded by the anaphase-promoting complex/cyclosome cofactor CDC20. Knockdown of CDC20 blocks Wnt signaling through conductin. CDC20-resistant conductin restrains Wnt signaling and lessens state development of colorectal malignant cells. It was reported that CDC20-mediated inhibition of conductin manages Wnt/ β -catenin signaling for high activity during G1/S [16].

SUMMARY

Wnt proteins are a group of cysteine rich glycoproteins that assume a part amid improvement and in growth. Three Wnt signaling pathways have been depicted in this way: the beta-catenin pathway (authoritative pathway), the planar cell extremity pathway and the Wnt/ Ca^{2+} pathway.

The Wnt pathway induces the formation of a complex of β -catenin in the cytoplasm and its immediate translocation into the core to act as a transcriptional coactivator of interpreting variables that binds with the TCF/LEF family. Without Wnt signaling, β -catenin would not aggregate in the cytoplasm since a demolition complex would regularly corrupt it. This catalytic complex incorporates the accompanying proteins: Axin, adenomatous polyposis coli (APC), protein phosphatase 2A (PP2A), glycogen synthase kinase 3 (GSK3) and casein kinase 1 α (CK1 α) [17, 18]. It degrades β -catenin by inducing ubiquitination, which in this manner sends it to the proteasome to be processed [19]. Nonetheless, when Wnt binds with Fz and LRP5/6, the active complex gets disturbed. This is because of Wnt promoting the translocation of the negative Wnt controller, Axin, and the annihilation complex to the plasma layer. Phosphorylation by different proteins in the decimation complex in this manner ties Axin to the cytoplasmic tail of LRP5/6. Axin gets to be de-phosphorylated and its strength and levels diminish. Dsh then gets to be actuated through phosphorylation and its DIX and PDZ areas repress the GSK3 movement of the decimation complex. This permits β -catenin to gather and restrict to the core and consequently instigate a cell reaction through signaltransduction close by the TCF/LEF (T-cell component/lymphoid upgrading element) [20].

Since its underlying discovery, Wnt signaling can be associated with growth. At the point when Wnt1 was found, it was initially distinguished as a proto-oncogene in a mouse model for breast tumor. The way that Wnt1 is a homolog of Wg demonstrates that it is included in embryonic advancement, which frequently calls for rapid cell division and relocation. Deregulation of these procedures can prompt tumor improvement through abundance cell expansion.

Canonical Wnt activity pathway is included in the advancement of massive and harmful breast tumors. Its proximity is uncovered by raised levels of β -catenin in the core and/or cytoplasm, which can be distinguished with immune-histochemical recoloring and Western smudging techniques. Expanded β -catenin expression is related with poor forecast in breast disease patients. This complex formation is because of elements, for example, transformations in β -catenin, lacks in the β -catenin pulverization involvement, most as often as possible by changes in fundamentally disarranged regions of APC, overexpression of Wnt ligands, loss of inhibitors and/or diminished action of administrative pathways, (for example, the Wnt/calcium pathway) [22]. Breast tumors can metastasize because of Wnt association in EMT. Research taking a gander at metastasis of basal-like Breast growth to the lungs demonstrated that inhibition of Wnt/ β -catenin signaling can anticipate EMT, which can hinder metastasis [21-24].

Wnt signaling was involved in the advancement of different malignancies. Changes in CTNNB1 expression, which is the signal that encodes β -catenin, can be measured in breast colorectal, melanoma, prostate, lung, and different diseases. Expanded articulation of Wnt ligand-proteins, for example, Wnt 1, Wnt2 and Wnt7A were seen in the advancement of glioblastoma, oesophageal malignancy and ovarian growth individually. Different proteins that cause various diseases without appropriate working incorporate ROR1, ROR2, SFRP4, Wnt5A, WIF1 and those of the TCF/LEF family [25].

REFERENCES

1. <http://www.cancer.ca/en/cancer-information/cancer-101/what-is-cancer/the-cell-cycle/?region=on>
2. http://www.cyclacel.com/research_science_cell-cycle.shtml
3. Logan CY and Nusse R. The Wnt signalling pathway in development and disease. *Annu Rev Cell Dev Biol.* 2004;20:781-810.
4. Niehrs C and Acebron SP. Mitotic and mitogenic Wnt signalling. *EMBO J.* 2012;31:2705-2713.
5. Sherwood V. WNT Signaling: an Emerging Mediator of Cancer Cell Metabolism? *Mol Cell Biol.* 2015;35:2-10.
6. Polakis P. Wnt signaling and cancer. *Genes & Dev.* 2000;14:1837-1851.

7. Reya T and Clevers H. Wnt signalling in stem cells and cancer. *Nature*. 2005;434:843-850.
8. Schulte G and Bryja V. The Frizzled family of unconventional G-protein-coupled receptors. *Trends in Pharmacol Sci*. 2007;28:518–525.
9. Komiya Y and Habas R. Wnt signal transduction pathways. *Organogenesis*. (2008);4:68-75.
10. He X, et al. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signalling: arrows point the way. *Development*. 2004;131:1663-1677.
11. Christof N and Sergio PA. Mitotic and mitogenic Wnt signalling. *EMBO J*. 2012;31:2705–2713.
12. Hadjihannas MV, et al. Cell cycle control of Wnt/ β -catenin signalling by conductin/axin2 through CDC20. *EMBO Rep* 2012;13:347-54.
13. Minde DP, et al. Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer? *Molecular Cancer*. 2011;10:101.
14. Minde DP, et al. Large Extent of Disorder in Adenomatous Polyposis Coli Offers a Strategy to Guard Wnt Signalling against Point Mutations. *PLoS ONE*. 2013;8:e77257.
15. Rao TP and Kühn M An updated overview on Wnt signaling pathways: a prelude for more. *Circ Res*. 2010;106:1798–1806.
16. MacDonald BT, et al. Wnt/beta-catenin signaling: components, mechanisms, and diseases. *Dev Cell*. 2009;17:9-26.
17. Nusse R. Wnt signaling in disease and in development. *Cell Research*. 2005;15:28–32.
18. Howe LR and Brown AM. Wnt signaling and breast cancer. *Cancer Biol Ther*. 2004;3:36-41.
19. Taketo MM. Shutting down Wnt signal-activated cancer. *Nature Genetics*. 2004;36:320–322.
20. DiMeo TA, et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. *Cancer Res*. 2009;69:5364–5373.
21. Anastas JN and Moon RT. WNT signalling pathways as therapeutic targets in cancer. *Nature Reviews Cancer*. 2013;13:11-26.
22. Lin MR, et al. Hyaluronan Elevates Cell Cycle Regulators P130, E2F4, and P27kip1 in Dormant Human Mesenchymal Stem Cells to Regulate Cell Quiescence. *J Stem Cell Res Ther*. 2016;6:345.
23. Kenji Sugimoto. Molecular Behavior of CENP-A and PCNA throughout the Cell Cycle in Living Human HT-1080 Cells. *Mol Biol* 2016;160.
24. Zhu M, et al. Alpha Fetoprotein Plays Antagonistic Role in Benzyl-Isothiocyanate Arresting Cell Cycle in Liver Cancer Cells. *Chemo Open Access*. 2016;5:195.
25. Zandrea M, et al. Radio sensitization of Colon Cancer Cells Mediated by Gemcitabine through Cell Cycle Synchronization. *J Carcinog Mutagen*. 2015;6:239.